Effect of Intratracheal Dexmedetomidine Administration on Recovery From General Anesthesia in Pediatrics Undergoing Lower Abdominal Surgery:

Model scores of the 29,894 trials active now.

Model score 8% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 10% of the time (273 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-01-01. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 0.3% (lowers risk) · Sponsor's track record
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: hearteffect ofpressureedemarenal
  Phrases that lowered it: asageneraldisordersirritationrespiratory
• Accepts healthy volunteers: No (raises risk) · Who can join
• Has a data monitoring committee: not given (lowers risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Blinding: quadruple (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports with a death: 16.3% (lowers risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 305 (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 1 (lowers risk) · Who can join
• Sponsor's past trials: 307 (lowers risk) · Sponsor's track record
• Phase: 2/3 (raises risk) · Design
• Number of arms: 2 (raises risk) · Design
• Maximum age: 6 (raises risk) · Who can join
• Drug's FAERS reports marked serious: 92.6% (raises risk) · Drug's FDA history
• Drug's FAERS reports before start: 2527 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Dexmedetomidine Infusion Dose Versus Rapid Bolus Dose Before Tracheal Intubation. NCT06327399 · started 2024 · scored riskier than 8% of active trials completed
• Effect of Dexmedetomidine on Stress Response and Emergence Agitation During Laparoscopic Surgery NCT02917018 · started 2016 · scored riskier than 8% of active trials completed
• Pharmacokinetics and Dynamics of Dexmedetomidine as Adjuvant in TAP Block NCT03328299 · started 2017 · scored riskier than 10% of active trials completed
• Role of Intravenous Dexmedetomidine in Reducing Shivering After Shivering Cesarean Section Due to Spinal Anesthesia NCT06711913 · started 2023 · scored riskier than 12% of active trials completed
• Dexmedetomidine in Reducing Incidence of Emergence Agitation After Nasal Surgery NCT05634148 · started 2022 · scored riskier than 7% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.